REFERENCES
1. Morgenstern DA, Bagatell R, Cohn SL, et al. The challenge of defining ”ultra-high-risk” neuroblastoma. Pediatr Blood Cancer.2019;66(4):e27556.
2. Moreno L, Guo D, Irwin MS, et al. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project.Pediatr Blood Cancer. 2021;68(3):e28794.
3. Morgenstern DA, Potschger U, Moreno L, et al. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study. Pediatr Blood Cancer. 2018;65(11):e27363.
4. Ohira M, Nakamura Y, Takimoto T, et al. Retrospective Analysis of INRG Clinical and Genomic Factors for 605 Neuroblastomas in Japan: A Report from the Japan Children’s Cancer Group Neuroblastoma Committee (JCCG-JNBSG). Biomolecules. 2022;12(1).
5. Hishiki T, Matsumoto K, Ohira M, et al. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).Int J Clin Oncol. 2018;23(5):965-973.
6. Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.JAMA. 2019;322(8):746-755.